FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001048215> ?p ?o ?g. }

• W2001048215 endingPage "352" @default.
• W2001048215 startingPage "344" @default.
• W2001048215 abstract "Hepatitis C is a leading cause of chronic liver disease in the United States, and the prevalence of hepatitis C–associated complications is increasing. Therapy with pegylated interferon and ribavirin has become the standard of care for chronic hepatitis C; the sustained response rate for treatment-naïve patients is about 55%. If certain patients fail to achieve a 12-week treatment milestone, an early virologic response, they may be taken off treatment early, potentially sparing them from unnecessary medication. Adherence is critical for treatment success. Although side effects continue to be a hindrance to the success of therapy, agents such as growth factors and antidepressants may help patients to maintain medication dosing and complete treatment. Therapy is generally recommended for those in whom the infection is most likely to progress to cirrhosis; however, there is continued debate about the suitability of certain patients for treatment, including those with persistently normal aminotransferase levels or acute hepatitis C and nonresponders to conventional treatment. Four broad groups of investigational therapeutic agents appear promising for future therapy: modified interferons and ribavirins, immunomodulators, viral life-cycle targets, and antifibrotic agents. Hepatitis C is a leading cause of chronic liver disease in the United States, and the prevalence of hepatitis C–associated complications is increasing. Therapy with pegylated interferon and ribavirin has become the standard of care for chronic hepatitis C; the sustained response rate for treatment-naïve patients is about 55%. If certain patients fail to achieve a 12-week treatment milestone, an early virologic response, they may be taken off treatment early, potentially sparing them from unnecessary medication. Adherence is critical for treatment success. Although side effects continue to be a hindrance to the success of therapy, agents such as growth factors and antidepressants may help patients to maintain medication dosing and complete treatment. Therapy is generally recommended for those in whom the infection is most likely to progress to cirrhosis; however, there is continued debate about the suitability of certain patients for treatment, including those with persistently normal aminotransferase levels or acute hepatitis C and nonresponders to conventional treatment. Four broad groups of investigational therapeutic agents appear promising for future therapy: modified interferons and ribavirins, immunomodulators, viral life-cycle targets, and antifibrotic agents." @default.
• W2001048215 created "2016-06-24" @default.
• W2001048215 creator A5043998553 @default.
• W2001048215 date "2004-09-01" @default.
• W2001048215 modified "2023-09-27" @default.
• W2001048215 title "Hepatitis C treatment update" @default.
• W2001048215 cites W1212464357 @default.
• W2001048215 cites W1874253413 @default.
• W2001048215 cites W1966509200 @default.
• W2001048215 cites W1967982404 @default.
• W2001048215 cites W1969811034 @default.
• W2001048215 cites W1972091708 @default.
• W2001048215 cites W1973050866 @default.
• W2001048215 cites W1976957825 @default.
• W2001048215 cites W1978339383 @default.
• W2001048215 cites W1978606949 @default.
• W2001048215 cites W1979003966 @default.
• W2001048215 cites W1992239172 @default.
• W2001048215 cites W1993484328 @default.
• W2001048215 cites W1996810729 @default.
• W2001048215 cites W2000674705 @default.
• W2001048215 cites W2004602615 @default.
• W2001048215 cites W2005863439 @default.
• W2001048215 cites W2011707824 @default.
• W2001048215 cites W2013816787 @default.
• W2001048215 cites W2015533723 @default.
• W2001048215 cites W2015608202 @default.
• W2001048215 cites W2017960775 @default.
• W2001048215 cites W2027545702 @default.
• W2001048215 cites W2027853774 @default.
• W2001048215 cites W2036313720 @default.
• W2001048215 cites W2044877748 @default.
• W2001048215 cites W2045210015 @default.
• W2001048215 cites W2045346511 @default.
• W2001048215 cites W2051126700 @default.
• W2001048215 cites W2052909219 @default.
• W2001048215 cites W2057302284 @default.
• W2001048215 cites W2058524504 @default.
• W2001048215 cites W2066836200 @default.
• W2001048215 cites W2066915530 @default.
• W2001048215 cites W2067435274 @default.
• W2001048215 cites W2070709974 @default.
• W2001048215 cites W2078450406 @default.
• W2001048215 cites W2078887917 @default.
• W2001048215 cites W2079453536 @default.
• W2001048215 cites W2085261733 @default.
• W2001048215 cites W2086365400 @default.
• W2001048215 cites W2090686755 @default.
• W2001048215 cites W2090712151 @default.
• W2001048215 cites W2091425424 @default.
• W2001048215 cites W2094883696 @default.
• W2001048215 cites W2098618513 @default.
• W2001048215 cites W2102785869 @default.
• W2001048215 cites W2103529803 @default.
• W2001048215 cites W2103638317 @default.
• W2001048215 cites W2109048688 @default.
• W2001048215 cites W2109499069 @default.
• W2001048215 cites W2111763105 @default.
• W2001048215 cites W2112876622 @default.
• W2001048215 cites W2115080342 @default.
• W2001048215 cites W2116442049 @default.
• W2001048215 cites W2116460737 @default.
• W2001048215 cites W2119168386 @default.
• W2001048215 cites W2119266617 @default.
• W2001048215 cites W2121238034 @default.
• W2001048215 cites W2127685726 @default.
• W2001048215 cites W2133528239 @default.
• W2001048215 cites W2140259908 @default.
• W2001048215 cites W2142684817 @default.
• W2001048215 cites W2144518798 @default.
• W2001048215 cites W2149727205 @default.
• W2001048215 cites W2151898297 @default.
• W2001048215 cites W2165715544 @default.
• W2001048215 cites W2314619766 @default.
• W2001048215 cites W2317554121 @default.
• W2001048215 cites W2324539587 @default.
• W2001048215 cites W2327525734 @default.
• W2001048215 cites W2341829866 @default.
• W2001048215 cites W4231272364 @default.
• W2001048215 cites W4244619221 @default.
• W2001048215 cites W4247506833 @default.
• W2001048215 cites W4250590377 @default.
• W2001048215 cites W4256582478 @default.
• W2001048215 doi "https://doi.org/10.1016/j.amjmed.2004.03.024" @default.
• W2001048215 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15336584" @default.
• W2001048215 hasPublicationYear "2004" @default.
• W2001048215 type Work @default.
• W2001048215 sameAs 2001048215 @default.
• W2001048215 citedByCount "78" @default.
• W2001048215 countsByYear W20010482152012 @default.
• W2001048215 countsByYear W20010482152013 @default.
• W2001048215 countsByYear W20010482152014 @default.
• W2001048215 countsByYear W20010482152015 @default.
• W2001048215 countsByYear W20010482152017 @default.
• W2001048215 countsByYear W20010482152018 @default.
• W2001048215 crossrefType "journal-article" @default.
• W2001048215 hasAuthorship W2001048215A5043998553 @default.
• W2001048215 hasConcept C120060458 @default.

• next